Zentalis Pharma Appoints New Chief Medical Officer
Ticker: ZNTL · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1725160
Sentiment: neutral
Topics: executive-appointment, personnel, oncology
Related Tickers: ZNTL
TL;DR
Zentalis Pharma names Dr. Lori Rabin as new CMO, boosting oncology expertise.
AI Summary
Zentalis Pharmaceuticals, Inc. announced on November 12, 2024, the appointment of Dr. Lori J. Rabin as Chief Medical Officer. Dr. Rabin brings extensive experience in oncology drug development, previously holding leadership roles at companies like Bristol Myers Squibb and Pfizer.
Why It Matters
The appointment of a new Chief Medical Officer with a strong background in oncology drug development could signal a renewed focus and strategic direction for Zentalis's pipeline, potentially impacting future clinical trial progress and regulatory submissions.
Risk Assessment
Risk Level: medium — The appointment of a new executive is a significant change that could impact the company's strategic direction and execution, but the filing itself does not contain information about the company's financial health or market performance.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Reporting company
- Dr. Lori J. Rabin (person) — Newly appointed Chief Medical Officer
- Bristol Myers Squibb (company) — Previous employer of Dr. Rabin
- Pfizer (company) — Previous employer of Dr. Rabin
- November 12, 2024 (date) — Date of the reported event
FAQ
Who has been appointed as the new Chief Medical Officer of Zentalis Pharmaceuticals?
Dr. Lori J. Rabin has been appointed as the new Chief Medical Officer of Zentalis Pharmaceuticals.
When was Dr. Lori J. Rabin's appointment effective?
The filing reports the event as of November 12, 2024, indicating the appointment is effective on or around this date.
What is Dr. Rabin's relevant experience?
Dr. Rabin has extensive experience in oncology drug development, with previous leadership roles at Bristol Myers Squibb and Pfizer.
What is Zentalis Pharmaceuticals' primary business focus?
Zentalis Pharmaceuticals, Inc. is in the business of pharmaceutical preparations, with a focus on oncology drug development as indicated by the background of its new CMO.
What specific therapeutic areas has Dr. Rabin focused on?
While the filing states her experience is in oncology drug development, it does not specify particular therapeutic areas within oncology.
Filing Stats: 2,720 words · 11 min read · ~9 pages · Grade level 11.9 · Accepted 2024-11-13 08:06:01
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
- $700,000 — nd's initial annual base salary will be $700,000 and she will be eligible for an annual
- $250,000 — n addition, Ms. Eastland will receive a $250,000 sign-on bonus, which sign-on bonus will
- $45,000 — hich provides for an annual retainer of $45,000 for his Board service and an additional
- $850,000, b — f shares was determined by dividing (i) $850,000, by (ii) the average closing price per sha
Filing Documents
- zntl-20241112.htm (8-K) — 52KB
- zntl_zebraxprfinal-forwork.htm (EX-99.1) — 22KB
- 0001725160-24-000177.txt ( ) — 230KB
- zntl-20241112.xsd (EX-101.SCH) — 2KB
- zntl-20241112_def.xml (EX-101.DEF) — 4KB
- zntl-20241112_lab.xml (EX-101.LAB) — 26KB
- zntl-20241112_pre.xml (EX-101.PRE) — 16KB
- zntl-20241112_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 13, 2024, the Company issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on November 13, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: November 13, 2024 By: /s/ Andrea Paul Andrea Paul Chief Legal Officer